BioClinica partnership to support 'continuum of pharmacovigilance services'

By Melissa Fassbender contact

- Last updated on GMT

Bioclinica is actively partnering to provide innovative offering models and technologies. (Image: iStock/zakokor)
Bioclinica is actively partnering to provide innovative offering models and technologies. (Image: iStock/zakokor)

Related tags: Artificial intelligence

BioClinica and ArisGlobal have partnered to offer customers a comprehensive pharmacovigilance service as "one size fits all" model evolves.

As part of the agreement, BioClinica becomes ArisGlobal’s preferred partner in business process consulting and change management as sponsors implement or upgrade ARISg, ArisGlobal’s pharmacovigilance and clinical safety system.

The cloud-based solution helps facilitate drug development and regulatory compliance throughout the entire product life cycle.

We decided to partner with ArisGlobal because we saw the opportunity to offer a continuum of pharmacovigilance services that can fit the needs of sponsors and CROs as those needs change, whether sponsors are growing, merging, experiencing a surge or a drop in safety events​,” Mukhtar Ahmed, BioClinica President eHealth Solutions​, told Outsourcing-Pharma.com. “In the same way that therapies are moving from a ‘one size fits all’ model, so is our offering model​.”

According to the company, the partners are currently working to develop ArisGlobal’s next generation of products, which will combine medical knowledge with technologies derived from such areas as artificial intelligence, machine learning, and natural language processing.

BioClinica benefits by offering solutions that fit the evolving needs of sponsors, thereby becoming a trusted provider across the research landscape​,” added Ahmed.

Bioclinica is actively partnering​ to provide innovative offering models and technologies. Ahmed told us, “You can expect to see new partners and members of our App xChange throughout the year as we build our program to provide value to sponsors​.”

Related news

Show more

Related products

show more

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us

Products

View more

Webinars